Nordic Life Science 1
TOP STORIES BUS INESS DEAL Genmab to acquire Meru
s for USD 8 billion Following the closing of the transaction, Genmab will have four programs expected to drive multiple new drug launches by 2027. THE ADDITION of Merus’ lead asset, petosemtamab, to Genmab’s pipeline is a strategic fit and aligns with Genmab’s expertise in antibody therapy development and commercialization in oncology, the company states. Petosemtamab is an EGFRxLGR5 bispecific antibody with the potential to be both first- and best-in-class in head and neck cancer. It has been granted two Breakthrough Therapy Designations by the FDA for first- and second-line plus head and neck cancer indications. “The proposed acquisition has the potential to significantly accelerate our evolution to a global biotechnology leader by providing durable growth for the company well into the next decade,” says Jan van de Winkel, CEO, Genmab. A wholly owned subsidiary of Genmab will commence a tender offer for 100% of Merus’ common shares, which is anticipated to close by early 2026. NLS 8 | NORDICLIFESCIENCE.ORG “The proposed acquisition has the potential to significantly accelerate our evolution to a global biotechnology leader by providing durable growth for the company well into the next decade.” JAN VAN DE WINKEL PHOTO STIJN DOORS